Furthermore, two other cannabinoids, CBG and CBN (Figure 2), that did not show potential to act as AIs or ERα antagonists, but have growing pharmacological interest and have been studied in other breast cancer subtypes [75,76], were also included in our study. This evidence concerns the gene ESR1 and breast carcinoma.